NEW YORK, June 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
http://www.reportlinker.com/p0546768/Myelodysplastic-Syndrome-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global myelodysplastic syndrome (MDS) therapeutic market. The report identifies the key trends shaping and driving the global MDS therapeutic market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MDS therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global myelodysplastic syndrome (MDS) market was valued at $652.6m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 12.2% to reach $1.5 billion by 2017. This growth forecast is primarily attributed to the currently approved drugs reaching their peak sales during the forecast period and secondarily due to a strong pipeline. The existing market is strong although with high unmet need. The market is represented by three approved drugs Vidaza (azacitidine), Dacogen (decitabine) and Revlimid (lenalidomide).
Scope
The report provides information on the key drivers and challenges of the MDS therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) MDS therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as HDCA (Histone deacetylase inhibitors) inhibitors, anti–CD33 mAb (monoclonal antibody) and VEGF (vascular endothelial growth receptor) inhibitors.
- Analysis of the current and future competition in the seven key countries MDS therapeutics market. Key market players covered are Amgen Inc, Arno Therapeutics, Array Biopharma, Cyclacel Pharmaceuticals Inc, Medac GmbH, Novartis AG, Onconova Therapeutics, Sanofi-Aventis, Synta Pharmaceuticals, S* BIO Pte, Telik Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the MDS therapeutics market.
- Analysis of key recent licensing and partnership agreements in Myelodysplastic Syndrome Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global MDS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global MDS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global MDS therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Overview 6
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.4 Signs and Symptoms 9
2.5 Diagnosis 9
2.6 Treatment 10
2.7 GlobalData Pipeline Report Guidance 11
3 Myelodysplastic Syndrome: Market Characterization 12
3.1 Major Markets, Market Size (2005-2010) 12
3.2 Major Markets, Market Forecast (2010-2017) 14
3.3 US Market Size (2005-2010) 16
3.4 US Market Forecast (2010-2017) 17
3.5 France Market Size (2005-2010) 18
3.6 France Market Forecast (2010-2017) 19
3.7 Germany Market Size (2005-2010) 20
3.8 Germany Market Forecast (2010-2017) 21
3.9 Italy Market Size (2005-2010) 22
3.10 Italy Market Forecast (2010-2017) 23
3.11 Spain Market Size (2005-2010) 24
3.12 Spain Market Forecast (2010-2017) 25
3.13 UK Market Size (2005-2010) 26
3.14 UK Market Forecast (2010-2017) 27
3.15 Japan Market Size (2005-2010) 28
3.16 Japan Market Forecast (2010-2017) 29
3.17 Drivers and Barriers for Myelodysplastic Syndrome Therapeutic Market 30
3.17.1 Drivers for Myelodysplastic Syndrome Market 30
3.17.2 Barriers for Myelodysplastic Syndrome Market 30
3.18 Opportunity and Unmet Need 31
3.19 Key Takeaway 32
4 Myelodysplastic Syndrome Market: Competitive Assessment 33
4.1 Overview 33
4.1.1 Strategic Competitor Assessment 33
4.2 Myelodysplastic Syndrome Market Marketed Products Profile 34
4.2.1 Vidaza (azacytidine) 34
4.2.2 Dacogen (decitabine) 35
4.2.3 Revlimid (lenalidomide) 37
4.3 Key Takeaway 37
5 Myelodysplastic Syndrome: Pipeline Assessment 38
5.1 Overview 38
5.2 Strategic Pipeline Assessment 38
5.3 Myelodysplastic Syndrome Pipeline Analysis – Pipeline by Clinical Phases of Development 39
5.3.1 Myelodysplastic Syndrome Therapeutics – Phase III Clinical Pipeline 39
5.3.2 Myelodysplastic Therapeutics – Phase II Clinical Pipeline 40
5.3.3 Myelodysplastic Syndrome Therapeutics – Phase I Clinical Pipeline 41
5.3.4 Myelodysplastic Syndrome Therapeutics – Preclinical Pipeline 41
5.4 Myelodysplastic Syndrome Pipeline by Mechanism of Action 41
5.5 Myelodysplastic Syndrome Technology Trends Analytical Framework 43
5.6 Myelodysplastic Syndrome Clinical Pipeline by Monotherapy and Combination Therapy 44
5.7 Myelodysplastic Syndrome Therapeutics – Promising Drugs under Clinical Development 44
5.8 Molecule Profile for Promising Drugs under Clinical Development 45
5.8.1 Treosulfan 45
5.9 Key Takeaway 45
6 Myelodysplastic Syndrome Therapeutics – Clinical Trials Mapping 46
6.1 Clinical Trials Mapping by Region/Country 46
6.2 Clinical Trials Mapping by Phase 47
6.3 Clinical Trials Mapping by Trial Status 48
6.4 Clinical Trials Mapping by Prominent Sponsors 49
6.5 Participants in Therapeutic Clinical Trials - Companies 51
7 Myelodysplastic Syndrome Therapeutics: Strategic Assessment 52
7.1 Key Events Impacting the Future Market 52
7.2 Future Market Competition Scenario 53
8 Global Myelodysplastic Syndrome Therapeutics: Future Players in The Market 54
8.1 Introduction 54
8.2 Amgen Inc. 55
8.2.1 Company Overview 55
8.2.2 Financial Overview 55
8.2.3 Business Overview 56
8.3 Arno Therapeutics Inc. 59
8.3.1 Company Overview 59
8.3.2 Business Overview 59
8.4 Array Bippharma 60
8.4.1 Company Overview 60
8.5 Cyclacel Pharmaceuticals Inc. 62
8.5.1 Company Overview 62
8.6 Medac GmbH 63
8.6.1 Company Overview 63
8.7 Novartis AG 64
8.8 Onconova Therapeutics 69
8.8.1 Company Overview 69
8.9 Sanofi-Aventis 70
8.9.1 Company Overview 70
8.9.2 Financial Overview 70
8.9.3 Business Description 70
8.10 Synta Pharmaceuticals 74
8.10.1 Company Overview 74
8.10.2 Financial Overview 74
8.10.3 Business Overview 74
8.11 S* BIO Pte 76
8.11.1 Company Overview 76
8.12 Telik Inc. 77
8.12.1 Company Overview 77
8.12.2 Financial Overview 77
8.12.3 Business Overview 77
8.13 Other Companies in Pipeline – Tabular Presentation 78
9 Licensing and Partnership Deals 80
10 Global Myelodysplastic Syndrome Market: Appendix 81
10.1 Definitions 81
10.2 Acronyms 81
10.3 Research Methodology 83
10.3.1 Coverage 83
10.3.2 Secondary Research 83
10.3.3 Forecasting 84
10.3.4 Primary Research 86
10.3.5 Expert Panels 86
10.4 Contact Us 86
10.5 Disclaimer 86
10.6 Sources 87
1.1 List of Tables
Table 1: French-British-American Classification of MDS 6
Table 2: World Health Organisation Classification of MDS 7
Table 3: IPSS Point Chart for MDS 8
Table 4: IPSS Classification Chart for MDS 8
Table 5: MDS Therapeutics, Global, Market Revenue ($m), 2005-2010 12
Table 6: MDS Therapeutics, Global, Revenue Forecasts ($m), 2010-2017 14
Table 7: MDS Therapeutics, The US, Market Historical Revenue ($m), 2005-2010 16
Table 8: MDS Therapeutics, The US, Historical Revenue Forecasts ($m), 2010-2017 17
Table 9: MDS Therapeutics, France, Market Revenue ($m), 2005-2010 18
Table 10: MDS Therapeutics, France, Revenue Forecasts ($m), 2010-2017 19
Table 11: MDS Therapeutics, Germany, Market Revenue ($m), 2005-2010 20
Table 12: MDS Therapeutics, Germany, Revenue Forecasts ($m), 2010-2017 21
Table 13: MDS Therapeutics, Italy, Market Revenue ($m), 2005-2010 22
Table 14: MDS Therapeutics, Italy, Revenue Forecasts ($m), 2010-2017 23
Table 15: MDS Therapeutics, Spain, Market Revenue ($m), 2005-2010 24
Table 16: MDS Therapeutics, Spain, Revenue Forecasts ($m), 2010-2017 25
Table 17: MDS Therapeutics, The UK, Market Revenue ($m), 2005-2010 26
Table 18: MDS Therapeutics, The UK, Revenue Forecasts ($m), 2010-2017 27
Table 19: MDS Therapeutics, Japan, Market Revenue ($m), 2005-2010 28
Table 20: MDS Therapeutics, Japan, Revenue Forecasts ($m), 2010-2017 29
Table 21: MDS Therapeutics – Phase III Clinical Pipeline, 2011 39
Table 22: MDS Therapeutics – Phase II Clinical Pipeline, 2011 40
Table 23: MDS Therapeutics – Phase I Clinical Pipeline, 2011 41
Table 24: MDS Therapeutics – Preclinical Pipeline, 2011 41
Table 25: Mechanism of Action That Constitute the Others in the Above Pie Chart 42
Table 26: MDS Therapeutics – Promising Drugs Under Clinical Development, 2011 44
Table 27: MDS Clinical Trials by Region – Number, 2011 46
Table 28: MDS Clinical Trials by Phase and Country, 2011 47
Table 29: MDS Clinical Trials by Status and Country, 2011 48
Table 30: MDS Clinical Trials by Sponsors and Country, 2011 49
Table 31: MDS Clinical Trials by Prominent Sponsors, 2011 50
Table 32: Amgen – Promising Molecules in Pipeline for Oncology, 2011 55
Table 33: Amgen Inc, Deals 2009-2011 57
Table 34: Arno Therapeutics – Promising Molecules in Pipeline for Oncology, 2011 59
Table 35: Array Biopharma – Promising Molecules in Pipeline for Oncology, 2011 60
Table 36: Array Biopharma Deals, 2009-2011 61
Table 37: Cyclacel Pharma – Promising Molecules in Pipeline for Oncology, 2011 62
Table 38: Medac GmbH – Promising Molecules in Pipeline for Oncology, 2011 63
Table 39: Medac GmbH Deals, 2009-2011 63
Table 40: Novartis – Oncology Pipeline, 2010 65
Table 41: Novartis Deals, 2009-2010 66
Table 42: Onconova Therapeutics – Promising Molecules in Pipeline for Oncology, 2011 69
Table 43: Onconova Therapeutics Deals, 2009-2011 69
Table 44: Sanofi-Aventis – Promising Molecules in Pipeline for Oncology, 2011 71
Table 45: Sanofi-Aventis Key Deals, 2010-2011 72
Table 46: Synta Pharmaceuticals – Promising Molecules in Pipeline for Oncology, 2011 74
Table 47: Synta Pharmaceuticals Deals, 2009-2011 75
Table 48: S* BIO Pte – Promising Molecules in Pipeline for Oncology, 2011 76
Table 49: Telik – Promising Molecules in Pipeline for Oncology, 2011 77
Table 50: Other Companies that have Molecules for MDS in Pipeline 78
Table 51: MDS Therapeutics, Licensing and Partnership Deals 80
1.2 List of Figures
Figure 1: MDS Therapeutics, Global, Market Revenue ($m), 2005-2010 12
Figure 2: MDS Therapeutics, Market Share ($m, %), 2010 13
Figure 3: MDS Therapeutics, Global, Revenue Forecasts ($m), 2010-2017 14
Figure 4: MDS Therapeutics, Forecast Market Share ($m, %), 2017 15
Figure 5: MDS Therapeutics, The US, Market Revenue ($m), 2005-2010 16
Figure 6: MDS Therapeutics, The US, Revenue Forecasts ($m), 2010-2017 17
Figure 7: MDS Therapeutics, France, Market Revenue ($m), 2005-2010 18
Figure 8: MDS Therapeutics, France, Revenue Forecasts ($m), 2010-2017 19
Figure 9: MDS Therapeutics, Germany, Market Revenue ($m), 2005-2010 20
Figure 10: MDS Therapeutics, Germany, Revenue Forecasts ($m), 2010-2017 21
Figure 11: MDS Therapeutics, Italy, Market Revenue ($m), 2005-2010 22
Figure 12: MDS Therapeutics, Italy, Revenue Forecasts ($m), 2010-2017 23
Figure 13: MDS Therapeutics, Spain, Market Revenue ($m), 2005-2010 24
Figure 14: MDS Therapeutics, Spain, Revenue Forecasts ($m), 2010-2017 25
Figure 15: MDS Therapeutics, The UK, Market Revenue ($m), 2005-2010 26
Figure 16: MDS Therapeutics, The UK, Revenue Forecasts ($m), 2010-2017 27
Figure 17: MDS Therapeutics, Japan, Market Revenue ($m), 2005-2010 28
Figure 18: MDS Therapeutics, Japan, Revenue Forecasts ($m), 2010-2017 29
Figure 19: Opportunity and Unmet Need in the MDS Therapeutic Market 31
Figure 20: Strategic Competitor Assessment of Marketed Products for MDS, 2010 33
Figure 21: Pipeline Products by Phase of Clinical Development, 2011 38
Figure 22: MDS Therapeutics Pipeline by Phase of Clinical Development, 2011 39
Figure 23: MDS Market – Clinical Pipeline by Mechanism Of Action, 2011 41
Figure 24: Technology Trends Analytical Framework of The MDS Pipeline, 2011 43
Figure 25: Technology Trends Analytical Framework of The MDS Pipeline - Description, 2011 43
Figure 26: MDS pipeline by The Nature of Therapy, 2011 44
Figure 27: MDS Clinical Trials by Region, 2011 46
Figure 28: MDS Clinical Trials by Phase, 2011 47
Figure 29: MDS Clinical Trials by Status, 2011 48
Figure 30: MDS Clinical Trials by Sponsors, 2011 49
Figure 31: MDS Clinical Trials by Prominent Sponsors, 2011 50
Figure 32: MDS Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 51
Figure 33: MDS Therapeutics, Key Events Impacting Future Market 52
Figure 34: MDS Therapeutics, Strategic Assessment, 2011 53
Figure 35: MDS Therapeutics, Clinical Pipeline by Company, 2011 54
Figure 36: GlobalData market Forecasting Model, 2011 85
Companies Mentioned
Amgen Inc.
Arno Therapeutics Inc.
Array Bippharma
Cyclacel Pharmaceuticals Inc.
Medac GmbH
Novartis AG
Onconova Therapeutics
Sanofi-Aventis
Synta Pharmaceuticals
S* BIO Pte
Telik Inc.
To order this report:
Pathology Industry: Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
http://www.reportlinker.com/p0546768/Myelodysplastic-Syndrome-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Advertisement
Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global myelodysplastic syndrome (MDS) therapeutic market. The report identifies the key trends shaping and driving the global MDS therapeutic market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MDS therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global myelodysplastic syndrome (MDS) market was valued at $652.6m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 12.2% to reach $1.5 billion by 2017. This growth forecast is primarily attributed to the currently approved drugs reaching their peak sales during the forecast period and secondarily due to a strong pipeline. The existing market is strong although with high unmet need. The market is represented by three approved drugs Vidaza (azacitidine), Dacogen (decitabine) and Revlimid (lenalidomide).
Scope
The report provides information on the key drivers and challenges of the MDS therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) MDS therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as HDCA (Histone deacetylase inhibitors) inhibitors, anti–CD33 mAb (monoclonal antibody) and VEGF (vascular endothelial growth receptor) inhibitors.
- Analysis of the current and future competition in the seven key countries MDS therapeutics market. Key market players covered are Amgen Inc, Arno Therapeutics, Array Biopharma, Cyclacel Pharmaceuticals Inc, Medac GmbH, Novartis AG, Onconova Therapeutics, Sanofi-Aventis, Synta Pharmaceuticals, S* BIO Pte, Telik Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the MDS therapeutics market.
- Analysis of key recent licensing and partnership agreements in Myelodysplastic Syndrome Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global MDS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global MDS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global MDS therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Overview 6
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.4 Signs and Symptoms 9
2.5 Diagnosis 9
2.6 Treatment 10
2.7 GlobalData Pipeline Report Guidance 11
3 Myelodysplastic Syndrome: Market Characterization 12
3.1 Major Markets, Market Size (2005-2010) 12
3.2 Major Markets, Market Forecast (2010-2017) 14
3.3 US Market Size (2005-2010) 16
3.4 US Market Forecast (2010-2017) 17
3.5 France Market Size (2005-2010) 18
3.6 France Market Forecast (2010-2017) 19
3.7 Germany Market Size (2005-2010) 20
3.8 Germany Market Forecast (2010-2017) 21
3.9 Italy Market Size (2005-2010) 22
3.10 Italy Market Forecast (2010-2017) 23
3.11 Spain Market Size (2005-2010) 24
3.12 Spain Market Forecast (2010-2017) 25
3.13 UK Market Size (2005-2010) 26
3.14 UK Market Forecast (2010-2017) 27
3.15 Japan Market Size (2005-2010) 28
3.16 Japan Market Forecast (2010-2017) 29
3.17 Drivers and Barriers for Myelodysplastic Syndrome Therapeutic Market 30
3.17.1 Drivers for Myelodysplastic Syndrome Market 30
3.17.2 Barriers for Myelodysplastic Syndrome Market 30
3.18 Opportunity and Unmet Need 31
3.19 Key Takeaway 32
4 Myelodysplastic Syndrome Market: Competitive Assessment 33
4.1 Overview 33
4.1.1 Strategic Competitor Assessment 33
4.2 Myelodysplastic Syndrome Market Marketed Products Profile 34
4.2.1 Vidaza (azacytidine) 34
4.2.2 Dacogen (decitabine) 35
4.2.3 Revlimid (lenalidomide) 37
4.3 Key Takeaway 37
5 Myelodysplastic Syndrome: Pipeline Assessment 38
5.1 Overview 38
5.2 Strategic Pipeline Assessment 38
5.3 Myelodysplastic Syndrome Pipeline Analysis – Pipeline by Clinical Phases of Development 39
5.3.1 Myelodysplastic Syndrome Therapeutics – Phase III Clinical Pipeline 39
5.3.2 Myelodysplastic Therapeutics – Phase II Clinical Pipeline 40
5.3.3 Myelodysplastic Syndrome Therapeutics – Phase I Clinical Pipeline 41
5.3.4 Myelodysplastic Syndrome Therapeutics – Preclinical Pipeline 41
5.4 Myelodysplastic Syndrome Pipeline by Mechanism of Action 41
5.5 Myelodysplastic Syndrome Technology Trends Analytical Framework 43
5.6 Myelodysplastic Syndrome Clinical Pipeline by Monotherapy and Combination Therapy 44
5.7 Myelodysplastic Syndrome Therapeutics – Promising Drugs under Clinical Development 44
5.8 Molecule Profile for Promising Drugs under Clinical Development 45
5.8.1 Treosulfan 45
5.9 Key Takeaway 45
6 Myelodysplastic Syndrome Therapeutics – Clinical Trials Mapping 46
6.1 Clinical Trials Mapping by Region/Country 46
6.2 Clinical Trials Mapping by Phase 47
6.3 Clinical Trials Mapping by Trial Status 48
6.4 Clinical Trials Mapping by Prominent Sponsors 49
6.5 Participants in Therapeutic Clinical Trials - Companies 51
7 Myelodysplastic Syndrome Therapeutics: Strategic Assessment 52
7.1 Key Events Impacting the Future Market 52
7.2 Future Market Competition Scenario 53
8 Global Myelodysplastic Syndrome Therapeutics: Future Players in The Market 54
8.1 Introduction 54
8.2 Amgen Inc. 55
8.2.1 Company Overview 55
8.2.2 Financial Overview 55
8.2.3 Business Overview 56
8.3 Arno Therapeutics Inc. 59
8.3.1 Company Overview 59
8.3.2 Business Overview 59
8.4 Array Bippharma 60
8.4.1 Company Overview 60
8.5 Cyclacel Pharmaceuticals Inc. 62
8.5.1 Company Overview 62
8.6 Medac GmbH 63
8.6.1 Company Overview 63
8.7 Novartis AG 64
8.8 Onconova Therapeutics 69
8.8.1 Company Overview 69
8.9 Sanofi-Aventis 70
8.9.1 Company Overview 70
8.9.2 Financial Overview 70
8.9.3 Business Description 70
8.10 Synta Pharmaceuticals 74
8.10.1 Company Overview 74
8.10.2 Financial Overview 74
8.10.3 Business Overview 74
8.11 S* BIO Pte 76
8.11.1 Company Overview 76
8.12 Telik Inc. 77
8.12.1 Company Overview 77
8.12.2 Financial Overview 77
8.12.3 Business Overview 77
8.13 Other Companies in Pipeline – Tabular Presentation 78
9 Licensing and Partnership Deals 80
10 Global Myelodysplastic Syndrome Market: Appendix 81
10.1 Definitions 81
10.2 Acronyms 81
10.3 Research Methodology 83
10.3.1 Coverage 83
10.3.2 Secondary Research 83
10.3.3 Forecasting 84
10.3.4 Primary Research 86
10.3.5 Expert Panels 86
10.4 Contact Us 86
10.5 Disclaimer 86
10.6 Sources 87
1.1 List of Tables
Table 1: French-British-American Classification of MDS 6
Table 2: World Health Organisation Classification of MDS 7
Table 3: IPSS Point Chart for MDS 8
Table 4: IPSS Classification Chart for MDS 8
Table 5: MDS Therapeutics, Global, Market Revenue ($m), 2005-2010 12
Table 6: MDS Therapeutics, Global, Revenue Forecasts ($m), 2010-2017 14
Table 7: MDS Therapeutics, The US, Market Historical Revenue ($m), 2005-2010 16
Table 8: MDS Therapeutics, The US, Historical Revenue Forecasts ($m), 2010-2017 17
Table 9: MDS Therapeutics, France, Market Revenue ($m), 2005-2010 18
Table 10: MDS Therapeutics, France, Revenue Forecasts ($m), 2010-2017 19
Table 11: MDS Therapeutics, Germany, Market Revenue ($m), 2005-2010 20
Table 12: MDS Therapeutics, Germany, Revenue Forecasts ($m), 2010-2017 21
Table 13: MDS Therapeutics, Italy, Market Revenue ($m), 2005-2010 22
Table 14: MDS Therapeutics, Italy, Revenue Forecasts ($m), 2010-2017 23
Table 15: MDS Therapeutics, Spain, Market Revenue ($m), 2005-2010 24
Table 16: MDS Therapeutics, Spain, Revenue Forecasts ($m), 2010-2017 25
Table 17: MDS Therapeutics, The UK, Market Revenue ($m), 2005-2010 26
Table 18: MDS Therapeutics, The UK, Revenue Forecasts ($m), 2010-2017 27
Table 19: MDS Therapeutics, Japan, Market Revenue ($m), 2005-2010 28
Table 20: MDS Therapeutics, Japan, Revenue Forecasts ($m), 2010-2017 29
Table 21: MDS Therapeutics – Phase III Clinical Pipeline, 2011 39
Table 22: MDS Therapeutics – Phase II Clinical Pipeline, 2011 40
Table 23: MDS Therapeutics – Phase I Clinical Pipeline, 2011 41
Table 24: MDS Therapeutics – Preclinical Pipeline, 2011 41
Table 25: Mechanism of Action That Constitute the Others in the Above Pie Chart 42
Table 26: MDS Therapeutics – Promising Drugs Under Clinical Development, 2011 44
Table 27: MDS Clinical Trials by Region – Number, 2011 46
Table 28: MDS Clinical Trials by Phase and Country, 2011 47
Table 29: MDS Clinical Trials by Status and Country, 2011 48
Table 30: MDS Clinical Trials by Sponsors and Country, 2011 49
Table 31: MDS Clinical Trials by Prominent Sponsors, 2011 50
Table 32: Amgen – Promising Molecules in Pipeline for Oncology, 2011 55
Table 33: Amgen Inc, Deals 2009-2011 57
Table 34: Arno Therapeutics – Promising Molecules in Pipeline for Oncology, 2011 59
Table 35: Array Biopharma – Promising Molecules in Pipeline for Oncology, 2011 60
Table 36: Array Biopharma Deals, 2009-2011 61
Table 37: Cyclacel Pharma – Promising Molecules in Pipeline for Oncology, 2011 62
Table 38: Medac GmbH – Promising Molecules in Pipeline for Oncology, 2011 63
Table 39: Medac GmbH Deals, 2009-2011 63
Table 40: Novartis – Oncology Pipeline, 2010 65
Table 41: Novartis Deals, 2009-2010 66
Table 42: Onconova Therapeutics – Promising Molecules in Pipeline for Oncology, 2011 69
Table 43: Onconova Therapeutics Deals, 2009-2011 69
Table 44: Sanofi-Aventis – Promising Molecules in Pipeline for Oncology, 2011 71
Table 45: Sanofi-Aventis Key Deals, 2010-2011 72
Table 46: Synta Pharmaceuticals – Promising Molecules in Pipeline for Oncology, 2011 74
Table 47: Synta Pharmaceuticals Deals, 2009-2011 75
Table 48: S* BIO Pte – Promising Molecules in Pipeline for Oncology, 2011 76
Table 49: Telik – Promising Molecules in Pipeline for Oncology, 2011 77
Table 50: Other Companies that have Molecules for MDS in Pipeline 78
Table 51: MDS Therapeutics, Licensing and Partnership Deals 80
1.2 List of Figures
Figure 1: MDS Therapeutics, Global, Market Revenue ($m), 2005-2010 12
Figure 2: MDS Therapeutics, Market Share ($m, %), 2010 13
Figure 3: MDS Therapeutics, Global, Revenue Forecasts ($m), 2010-2017 14
Figure 4: MDS Therapeutics, Forecast Market Share ($m, %), 2017 15
Figure 5: MDS Therapeutics, The US, Market Revenue ($m), 2005-2010 16
Figure 6: MDS Therapeutics, The US, Revenue Forecasts ($m), 2010-2017 17
Figure 7: MDS Therapeutics, France, Market Revenue ($m), 2005-2010 18
Figure 8: MDS Therapeutics, France, Revenue Forecasts ($m), 2010-2017 19
Figure 9: MDS Therapeutics, Germany, Market Revenue ($m), 2005-2010 20
Figure 10: MDS Therapeutics, Germany, Revenue Forecasts ($m), 2010-2017 21
Figure 11: MDS Therapeutics, Italy, Market Revenue ($m), 2005-2010 22
Figure 12: MDS Therapeutics, Italy, Revenue Forecasts ($m), 2010-2017 23
Figure 13: MDS Therapeutics, Spain, Market Revenue ($m), 2005-2010 24
Figure 14: MDS Therapeutics, Spain, Revenue Forecasts ($m), 2010-2017 25
Figure 15: MDS Therapeutics, The UK, Market Revenue ($m), 2005-2010 26
Figure 16: MDS Therapeutics, The UK, Revenue Forecasts ($m), 2010-2017 27
Figure 17: MDS Therapeutics, Japan, Market Revenue ($m), 2005-2010 28
Figure 18: MDS Therapeutics, Japan, Revenue Forecasts ($m), 2010-2017 29
Figure 19: Opportunity and Unmet Need in the MDS Therapeutic Market 31
Figure 20: Strategic Competitor Assessment of Marketed Products for MDS, 2010 33
Figure 21: Pipeline Products by Phase of Clinical Development, 2011 38
Figure 22: MDS Therapeutics Pipeline by Phase of Clinical Development, 2011 39
Figure 23: MDS Market – Clinical Pipeline by Mechanism Of Action, 2011 41
Figure 24: Technology Trends Analytical Framework of The MDS Pipeline, 2011 43
Figure 25: Technology Trends Analytical Framework of The MDS Pipeline - Description, 2011 43
Figure 26: MDS pipeline by The Nature of Therapy, 2011 44
Figure 27: MDS Clinical Trials by Region, 2011 46
Figure 28: MDS Clinical Trials by Phase, 2011 47
Figure 29: MDS Clinical Trials by Status, 2011 48
Figure 30: MDS Clinical Trials by Sponsors, 2011 49
Figure 31: MDS Clinical Trials by Prominent Sponsors, 2011 50
Figure 32: MDS Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 51
Figure 33: MDS Therapeutics, Key Events Impacting Future Market 52
Figure 34: MDS Therapeutics, Strategic Assessment, 2011 53
Figure 35: MDS Therapeutics, Clinical Pipeline by Company, 2011 54
Figure 36: GlobalData market Forecasting Model, 2011 85
Companies Mentioned
Amgen Inc.
Arno Therapeutics Inc.
Array Bippharma
Cyclacel Pharmaceuticals Inc.
Medac GmbH
Novartis AG
Onconova Therapeutics
Sanofi-Aventis
Synta Pharmaceuticals
S* BIO Pte
Telik Inc.
To order this report:
Pathology Industry: Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
